Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 65

Sort by

Sort Order Select

Meeting Abstracts

1663-P: The Impact of Time-Restricted Eating on Beta-Cell Function in Overweight Adults with Type 2 Diabetes—A Randomized Crossover trial

CAROLINE K. KRAMER, RAVI RETNAKARAN, BERNARD ZINMAN

Diabetes 2024;73(Supplement_1):1663-P

https://doi.org/10.2337/db24-1663-P

Published: 14 June 2024

View article titled, 1663-P: The Impact of Time-Restricted Eating on Beta-Cell Function in Overweight Adults with Type 2 Diabetes—A Randomized Crossover trial

Meeting Abstracts

255-OR: Postpartum Weight Retention and the Early Evolution of Cardiovascular Risk over the First 5 Years after Delivery

CAROLINE K. KRAMER, CHANG YE, ANTHONY HANLEY, PHILIP W. CONNELLY, BERNARD ZINMAN, RAVI RETNAKARAN

Diabetes 2023;72(Supplement_1):255-OR

https://doi.org/10.2337/db23-255-OR

Published: 20 June 2023

View article titled, 255-OR: Postpartum Weight Retention and the Early Evolution of Cardiovascular Risk over the First 5 Years after Delivery

Meeting Abstracts

180-OR: Baseline Predictors of Remission of Type 2 Diabetes in Response to Short-Term Insulin-Based Therapy—The Pivotal Role of Beta-Cell Function

RAVI RETNAKARAN, JIAJIE PU, ALEXANDRA EMERY, CAROLINE K. KRAMER, BERNARD ZINMAN

Diabetes 2023;72(Supplement_1):180-OR

https://doi.org/10.2337/db23-180-OR

Published: 20 June 2023

View article titled, 180-OR: Baseline Predictors of Remission of Type 2 Diabetes in Response to Short-Term Insulin-Based Therapy—The Pivotal Role of Beta-Cell Function

Meeting Abstracts

249-OR: Growth Trajectories of MiTy Kids' Offspring According to Intrauterine Growth Status

J. JOHANNA SANCHEZ, JILL HAMILTON, GEORGE TOMLINSON, ELIZABETH ASZTALOS, KELLIE MURPHY, BERNARD ZINMAN, DAVID SIMMONS, ANDREA HAQQ, IVAN G. FANTUS, LORRAINE LIPSCOMBE, ANTHONY ARMSON, JON F.R. BARRETT, LOIS E. DONOVAN, PAUL KARANICOLAS, YIDI JIANG, SIOBHAN TOBIN, KATHRYN MANGOFF, GAIL KLEIN, DENICE FEIG

Diabetes 2022;71(Supplement_1):249-OR

https://doi.org/10.2337/db22-249-OR

Published: 01 June 2022

View article titled, 249-OR: Growth Trajectories of MiTy Kids' Offspring According to Intrauterine Growth Status

Meeting Abstracts

248-OR: MiTy Kids: Follow-Up of Offspring Exposed to Metformin In-Utero in Mothers with Type 2 Diabetes in the MiTy Trial

DENICE FEIG, J. JOHANNA SANCHEZ, KELLIE MURPHY, ELIZABETH ASZTALOS, BERNARD ZINMAN, DAVID SIMMONS, ANDREA HAQQ, IVAN G. FANTUS, LORRAINE LIPSCOMBE, ANTHONY ARMSON, JON F.R. BARRETT, LOIS E. DONOVAN, PAUL KARANICOLAS, GAIL KLEIN, SIOBHAN TOBIN, KATHRYN MANGOFF, GEORGE TOMLINSON, JILL HAMILTON

Diabetes 2022;71(Supplement_1):248-OR

https://doi.org/10.2337/db22-248-OR

Published: 01 June 2022

View article titled, 248-OR: MiTy Kids: Follow-Up of Offspring Exposed to Metformin In-Utero in Mothers with Type 2 Diabetes in the MiTy Trial

Meeting Abstracts

721-P: Insulin-Sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8

VANITA R. ARODA, MORTEN T. ABILDLUND, RIKKE AGESEN, STEWART B. HARRIS, BANAFSHEH ZAHEDI, BERNARD ZINMAN, EIICHI ARAKI

Diabetes 2022;71(Supplement_1):721-P

https://doi.org/10.2337/db22-721-P

Published: 01 June 2022

View article titled, 721-P: Insulin-Sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8

Meeting Abstracts

133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE

KATHRYN CARDOZA, AMY KANG, BRENDAN SMYTH, TAE WON YI, GIAN LUCA DI TANNA, CAROL A. POLLOCK, DICK DE ZEEUW, DAVID C. WHEELER, CHRISTOPHER P. CANNON, BERNARD ZINMAN, MEG J. JARDINE, CLARE ARNOTT, ADEERA LEVIN, KENNETH W. MAHAFFEY

Diabetes 2021;70(Supplement_1):133-LB

https://doi.org/10.2337/db21-133-LB

Published: 01 June 2021

View article titled, 133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE

Meeting Abstracts

129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

Diabetes 2021;70(Supplement_1):129-LB

https://doi.org/10.2337/db21-129-LB

Published: 01 June 2021

View article titled, 129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

Meeting Abstracts

790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME

SILVIO E. INZUCCHI, CHRISTOPH WANNER, DAVID H. FITCHETT, BERNARD ZINMAN, STEFAN ANKER, MICHAELA MATTHEUS, OLA VEDIN, STEFAN HANTEL, SØREN S. LUND

Diabetes 2021;70(Supplement_1):790-P

https://doi.org/10.2337/db21-790-P

Published: 01 June 2021

View article titled, 790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME

Meeting Abstracts

131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

Diabetes 2021;70(Supplement_1):131-LB

https://doi.org/10.2337/db21-131-LB

Published: 01 June 2021

View article titled, 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

Meeting Abstracts

319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial

SABINE KAHL, ANNE PERNILLE OFSTAD, BERNARD ZINMAN, CHRISTOPH WANNER, ELKE SCHUELER, SILVIO E. INZUCCHI, MICHAEL RODEN

Diabetes 2021;70(Supplement_1):319-OR

https://doi.org/10.2337/db21-319-OR

Published: 01 June 2021

View article titled, 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial

Journal Articles

Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291–299

John M. Lachin, David M. Nathan, Bernard Zinman, Ionut Bebu

Diabetes 2020;69(7):e7–e8

https://doi.org/10.2337/db20-0311

Published: 15 June 2020

View article titled, Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291–299

Meeting Abstracts

162-OR: Interrelationship between Hypoglycemia (HYPO) and Cardiovascular (CV) and Mortality Outcomes in the CAROLINA Trial

JULIO ROSENSTOCK, NIKOLAUS MARX, DARREN K. MCGUIRE, BERNARD ZINMAN, MARK ESPELAND, JYOTHIS T. GEORGE, MICHAELA MATTHEUS, ODD ERIK JOHANSEN

Diabetes 2020;69(Supplement_1):162-OR

https://doi.org/10.2337/db20-162-OR

Published: 01 June 2020

View article titled, 162-OR: Interrelationship between Hypoglycemia (HYPO) and Cardiovascular (CV) and Mortality Outcomes in the CAROLINA Trial

Meeting Abstracts

30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

MUTHIAH VADUGANATHAN, NAVEED SATTAR, DAVID H. FITCHETT, ANNE PERNILLE OFSTAD, MARTINA BRUECKMANN, JYOTHIS T. GEORGE, SUBODH VERMA, MICHAELA MATTHEUS, CHRISTOPH WANNER, SILVIO E. INZUCCHI, BERNARD ZINMAN, JAVED BUTLER

Diabetes 2020;69(Supplement_1):30-OR

https://doi.org/10.2337/db20-30-OR

Published: 01 June 2020

View article titled, 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

Meeting Abstracts

926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial

MARK ESPELAND, RICHARD E. PRATLEY, JULIO ROSENSTOCK, TAKASHI KADOWAKI, YUTAKA SEINO, BERNARD ZINMAN, NIKOLAUS MARX, DARREN K. MCGUIRE, KNUT R. ANDERSEN, MICHAELA MATTHEUS, ANNETT KELLER, ODD ERIK JOHANSEN

Diabetes 2020;69(Supplement_1):926-P

https://doi.org/10.2337/db20-926-P

Published: 01 June 2020

View article titled, 926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial

Meeting Abstracts

952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial

BERNARD ZINMAN, JULIO ROSENSTOCK, ODD ERIK JOHANSEN, MIKKEL HOEIBERG, EGON PFARR, MICHAELA MATTHEUS, THOMAS MEINICKE, JYOTHIS T. GEORGE, MARK ESPELAND, DARREN K. MCGUIRE, NIKOLAUS MARX, STEVEN E. KAHN

Diabetes 2020;69(Supplement_1):952-P

https://doi.org/10.2337/db20-952-P

Published: 01 June 2020

View article titled, 952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial

Meeting Abstracts

956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin

OFRI MOSENZON, VANITA R. ARODA, ERIK CHRISTIANSEN, STEWART B. HARRIS, KAREN BOJE PEDERSEN, MADS JEPPE TARP-JOHANSEN, BERNARD ZINMAN

Diabetes 2020;69(Supplement_1):956-P

https://doi.org/10.2337/db20-956-P

Published: 01 June 2020

View article titled, 956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin

Meeting Abstracts

27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

Diabetes 2020;69(Supplement_1):27-OR

https://doi.org/10.2337/db20-27-OR

Published: 01 June 2020

View article titled, 27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

Meeting Abstracts

26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE

MEGUMI OSHIMA, MEG J. JARDINE, RAJIV AGARWAL, GEORGE BAKRIS, CHRISTOPHER CANNON, DAVID M. CHARYTAN, DICK DE ZEEUW, ROBERT EDWARDS, TOM GREENE, ADEERA LEVIN, KENNETH W. MAHAFFEY, BRUCE NEAL, CAROL A. POLLOCK, NORM ROSENTHAL, DAVID C. WHEELER, HONG ZHANG, BERNARD ZINMAN, VLADO PERKOVIC, HIDDO L. HEERSPINK

Diabetes 2020;69(Supplement_1):26-OR

https://doi.org/10.2337/db20-26-OR

Published: 01 June 2020

View article titled, 26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE

Meeting Abstracts

28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME

SUBODH VERMA, LAWRENCE A. LEITER, ABHINAV SHARMA, BERNARD ZINMAN, MICHAELA MATTHEUS, DAVID H. FITCHETT, JYOTHIS T. GEORGE, ANNE PERNILLE OFSTAD, CHRISTOPH WANNER, SILVIO E. INZUCCHI

Diabetes 2020;69(Supplement_1):28-OR

https://doi.org/10.2337/db20-28-OR

Published: 01 June 2020

View article titled, 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME

NARROW

1663-P: The Impact of Time-Restricted Eating on Beta-Cell Function in Overweight Adults with Type 2 Diabetes—A Randomized Crossover trial

255-OR: Postpartum Weight Retention and the Early Evolution of Cardiovascular Risk over the First 5 Years after Delivery

180-OR: Baseline Predictors of Remission of Type 2 Diabetes in Response to Short-Term Insulin-Based Therapy—The Pivotal Role of Beta-Cell Function

249-OR: Growth Trajectories of MiTy Kids' Offspring According to Intrauterine Growth Status

248-OR: MiTy Kids: Follow-Up of Offspring Exposed to Metformin In-Utero in Mothers with Type 2 Diabetes in the MiTy Trial

721-P: Insulin-Sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8

133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE

129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME

131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial

Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291–299

162-OR: Interrelationship between Hypoglycemia (HYPO) and Cardiovascular (CV) and Mortality Outcomes in the CAROLINA Trial

30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME

926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial

952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial

956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin

27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE

28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only